| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10051797 | HBV | ENSG00000115414.21 | protein_coding | FN1 | No | No | 2335 | B7ZLE5 P02751 |
| TVIS10045521 | HBV | ENSG00000115414.21 | protein_coding | FN1 | No | No | 2335 | B7ZLE5 P02751 |
| TVIS10047146 | HBV | ENSG00000115414.21 | protein_coding | FN1 | No | No | 2335 | B7ZLE5 P02751 |
| TVIS10047147 | HBV | ENSG00000115414.21 | protein_coding | FN1 | No | No | 2335 | B7ZLE5 P02751 |
| TVIS10049860 | HBV | ENSG00000115414.21 | protein_coding | FN1 | No | No | 2335 | B7ZLE5 P02751 |
| TVIS10045321 | HBV | ENSG00000115414.21 | protein_coding | FN1 | No | No | 2335 | B7ZLE5 P02751 |
| TVIS10051740 | HBV | ENSG00000115414.21 | protein_coding | FN1 | No | No | 2335 | B7ZLE5 P02751 |
| TVIS10052839 | HBV | ENSG00000115414.21 | protein_coding | FN1 | No | No | 2335 | B7ZLE5 P02751 |
| TVIS10051101 | HBV | ENSG00000115414.21 | protein_coding | FN1 | No | No | 2335 | B7ZLE5 P02751 |
| TVIS10048945 | HBV | ENSG00000115414.21 | protein_coding | FN1 | No | No | 2335 | B7ZLE5 P02751 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | FN1 |
|---|---|
| DrugBank ID | DB01593 |
| Drug Name | Zinc |
| Target ID | BE0001180 |
| UniProt ID | P02751 |
| Regulation Type | |
| PubMed IDs | 23896426 |
| Citations | Wang F, Chmil C, Pierce F, Ganapathy K, Gump BB, MacKenzie JA, Metchref Y, Bendinskas K: Immobilized metal affinity chromatography and human serum proteomics. J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Sep 1;934:26-33. doi: 10.1016/j.jchromb.2013.06.032. Epub 2013 Jul 5. |
| Groups | Approved; Investigational |
| Direct Classification | Homogeneous transition metal compounds |
| SMILES | [Zn] |
| Pathways | Dihydropyrimidinase Deficiency; Rofecoxib Action Pathway; Losartan Action Pathway; AICA-Ribosiduria; Canavan Disease; Quinapril Action Pathway; Alkaptonuria; Eprosartan Action Pathway; gamma-Glutamyltransferase Deficiency; Pterine Biosynthesis; Sulindac Action Pathway; Rescinnamine Action Pathway; Piroxicam Action Pathway; Nabumetone Action Pathway; 2-Hydroxyglutric Aciduria (D and L Form); beta-Ureidopropionase Deficiency; Vitamin B6 Metabolism; Retinol Metabolism; Valsartan Action Pathway; Valdecoxib Action Pathway; Irbesartan Action Pathway; Adenosine Deaminase Deficiency; Hawkinsinuria; Methionine Metabolism; Ramipril Action Pathway; Benazepril Action Pathway; beta-Alanine Metabolism; Aspartate Metabolism; Diclofenac Action Pathway; Galactosemia |
| PharmGKB | PA451956 |
| ChEMBL | CHEMBL1201279 |
